ReviewCold Spring Harbor perspectives in medicine2018
The Epidemiology of Prostate Cancer.
Review in Cold Spring Harbor perspectives in medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04873427 (In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies), which is not on this map. Cited by 398 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies: Impact on Prostate Cancer Evolution and Clinical Outcome. A Retrospective, Proof of Concept Study
Who cites it
398 citing papers in PubMed, 5 syntheses or guidelines pooled it, 749 citations in OpenAlex.
- Efficacy and safety of neoadjuvant therapies for high-risk and locally advanced prostate cancer in older adults: a systematic review and network meta-analysis.Frontiers in oncology · 2026Pooled it
- Perceptions, Knowledge, and Attitudes of General Population About Prostate Cancer-Associated Risk Factors: A Systematic Review of Qualitative Studies Focusing on Lifestyle.Current oncology reports · 2025Pooled it
- Ambient air pollution and urological cancer risk: A systematic review and meta-analysis of epidemiological evidence.Nature communications · 2024Pooled it
- Causal inference between rheumatoid arthritis and prostate cancer.Clinical and experimental medicine · 2023Pooled it
- Systemic lupus erythematosus and prostate cancer risk: a pool of cohort studies and Mendelian randomization analysis.Journal of cancer research and clinical oncology · 2023Pooled it
- Influence of Regular Statin Intake on Prostate-Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial (ERSPC Aarau).Cancer medicine · 2025Trial
- Trial
- Bipolar Androgen Therapy as a Potential Mechanistic Bridge to Enhance PARP Inhibitor Efficacy in Prostate Cancer.The Kaohsiung journal of medical sciences · 2026Article
- ADT and activation of HGF and WNT axes in double-null prostate cancer.Nature reviews. Urology · 2026Review
- The nutrigenomic-epigenetic axis in cancer: from dietary bioactives to precision oncology.Nutrition & metabolism · 2026Review
- Icariin suppresses glycolysis in prostate cancer by upregulating ALKBH5 to mediate EARS2 mJournal of molecular histology · 2026Article
- Histone lactatation-related genes GPR19 and SLC22A16 are important diagnostic markers and drug treatment targets for prostate cancer.Genes & genomics · 2026Article
- Article
- Review
- Genetic Testing and Imaging in Men with Familial History or Genetic Predisposition of Prostate Cancer-Introducing the Prospective "ProFam-Risk" Study.European urology open science · 2026Article
- Association between platelet-to-lymphocyte ratio and high risk for prostate cancer among middle-aged and older US men.Scientific reports · 2026Article
- NF-κB (p65, p50), IL-18, and IL-10 as Therapeutic Targets in Prostate Cancer and BPH: Molecular Insights into Inflammation-Driven Pathogenesis.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Determinants of the Cost of Illness in Iranian Prostate Cancer Patients.Prostate cancer · 2026Article
- Human papillomavirus in prostate cancer: examining the evidence for a co-factor role.Frontiers in microbiology · 2026Review
- RAB40C regulates SNX9 stabilityCentral-European journal of immunology · 2026Article
338 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a major cause of disease and mortality among men, and each year 1.6 million men are diagnosed with and 366,000 men die of prostate cancer. In this review, we discuss the state of evidence for specific genetic, lifestyle, and dietary factors associated with prostate cancer risk. Given the biological heterogeneity of this cancer, we focus on risk factors for advanced or fatal prostate cancer. First, we provide descriptive epidemiology statistics and patterns for prostate cancer incidence and mortality around the world. This includes discussion of the impact of prostate-specific antigen screening on prostate cancer epidemiology. Next, we summarize evidence for selected risk factors for which there is strong or probable evidence of an association: genetics, obesity and weight change, physical activity, smoking, lycopene and tomatoes, fish, vitamin D and calcium, and statins. Finally, we highlight future directions for prostate cancer epidemiology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.